|1.||Taisescu, Citto: 1 article (01/2015)|
|2.||Cai, Heng: 1 article (01/2015)|
|3.||Brindusa, Corina: 1 article (01/2015)|
|4.||Dricu, Anica: 1 article (01/2015)|
|5.||Purcaru, Stefana Oana: 1 article (01/2015)|
|6.||Li, Zhiqing: 1 article (01/2015)|
|7.||Tache, Daniela Elise: 1 article (01/2015)|
|8.||Tataranu, Ligia Gabriela: 1 article (01/2015)|
|9.||Liu, Yunhui: 1 article (01/2015)|
|10.||Alexandru, Oana: 1 article (01/2015)|
06/01/2011 - "Upregulated VEGF expression and release were prevented by SU1498, which also inhibited the hypoxia-induced pSTAT3 and HIF-1α. "
09/01/2008 - "The protective effects of NSPCs on ECs under conditions of serum starvation and hypoxia were blocked by pharmacological inhibitors of VEGF signaling, SU1498 and Flt-1-Fc. "
10/01/2005 - "VEGF, especially its isoform VEGF(165), and VEGFR-2 were also upregulated in retinal glial cells by hypoxia, and hypoxia-induced MT1-MMP expression was inhibited in the presence of the VEGFR-2 inhibitor SU1498 or the anti-VEGF antibody. "
|3.||Hepatocellular Carcinoma (Hepatoma)
10/01/2013 - "In the present study, we found that irradiation increased the invasiveness of human hepatoma HepG2 cells, and pretreatment of the cells with SU1498 (an inhibitor of vascular endothelial growth factor receptor 2, VEGFR2) and GM6001 (an inhibitor of matrix metalloproteinases 2, MMP2) demonstrated that radiation-enhanced invasiveness is associated with the interplay between MMP2 and VEGF signaling. "
08/06/2008 - "Moreover, APRPG-PEG-modified liposomal SU1498 significantly decreased tumor microvessel density in Colon26 NL-17 cell-bearing mice and prolonged the survival time of the mice. "
01/01/2008 - "OCT imaging of one matched pair demonstrated equivalent, linear tumor growth despite treatment with SU1498. "
01/01/2008 - "However, SU1498 did not significantly reduce tumor burden compared to vehicle (p=0.29). "
01/01/2008 - "OCT was used to pair 10-week-old animals based on tumor volume (n=10), and these animals were treated with 6 periocular injections of SU1498 (50mg/kg, given twice weekly) or vehicle for 3 weeks. "
08/06/2008 - "These findings suggest that APRPG-PEG-modified liposomes effectively deliver SU1498 to angiogenic endothelial cells in tumors and thus inhibit tumor-induced angiogenesis."
|5.||Epiretinal Membrane (Epiretinal Membranes)
08/01/2003 - "Hemizygous rhoPDGF-B or homozygous rho/PDGF-A mice were treated orally with PKC412 (an inhibitor of PDGF, VEGF, and c-kit receptor kinases and several isoforms of PKC), PTK787 (an inhibitor of PDGF, VEGF, and c-kit receptor kinases), SU1498 (an inhibitor of VEGF receptor kinases), imatinib mesylate (an inhibitor of PDGF, c-kit, and v-abl receptor kinases), or vehicle, and at appropriate time points epiretinal membrane (ERM) formation and retinal detachment were quantified. "
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|2.||Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
|5.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|6.||2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- one
|7.||Matrix Metalloproteinase 14 (MT1-MMP)
|9.||Protein Isoforms (Isoforms)